AI Bias Analysis
4 models · Takes ~15 seconds
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Source
Stat News
Opens original article in a new tab
(MedPage Today) -- I have spent 20 years working in out-of-network healthcare reimbursement. After reading the New York Times article "A $440,000 Breast Reduction? How Doctors Cash In on a Health Care Law," I felt the payer's use of the independent...
Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…
(MedPage Today) -- CHICAGO -- Combining two targeted therapies with standard-of-care chemotherapy extended progression-free survival (PFS) in patients with newly diagnosed B-cell lymphomas, according to data from the frontMIND trial. In the...
(MedPage Today) -- President Donald Trump on Friday gave his endorsement to a January study by HHS that calls for cutting the number of vaccines recommended for every American child. An executive order from Trump directs federal agencies to align...
